Abdullah Yahya Abdullah Alzahrani

Abdullah Yahya Abdullah Alzahrani

Auto-generated profile, based on publicly available information

Abdullah Yahya Abdullah Alzahrani

Department of Chemistry, Faculty of Science, King Khalid University, Abha 61413, Saudi Arabia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2026 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
RRRajalakshmi Ramarajan
Rajalakshmi Ramarajan
KEKarpagam Ezhilarasan
Karpagam Ezhilarasan
SNSatheeshkumar Nagaraj
Satheeshkumar Nagaraj
ARARULRAJ RAMALINGAM
ARULRAJ RAMALINGAM
AAAbdullah Yahya Abdullah Alzahrani
Abdullah Yahya Abdullah Alzahrani
Noureddine ISSAOUINoureddine ISSAOUI
Noureddine ISSAOUI

6 November 2026 in Comptes Rendus. Chimie
Verified
Journal Article
Closed access
IHIsraa Hakeem
Israa Hakeem
AAAbdullah Yahya Abdullah Alzahrani
Abdullah Yahya Abdullah Alzahrani
MAMunirah Muhammad Al-Rooqi
Munirah Muhammad Al-Rooqi
RJRabab Sharf Jassas
Rabab Sharf Jassas
MANZOOR A RATHERMANZOOR A RATHER
MANZOOR A RATHER
SASaleh A Ahmed
Saleh A Ahmed
Breast cancer (BC) is a frequently diagnosed cancer in women worldwide and imposes a significant burden on healthcare systems. Although chemotherapy remains a primary treatment modality, its efficacy is often compromised by multidrug resistance (MDR), leading to poor clinical outcomes and treatment failure. Multidrug resistance in BC arises through multiple mechanisms, including decreased apoptotic activity, overexpression of ATP-binding cassette (ABC) transporters, alterations in the tumor microenvironment, enhanced DNA repair capacity, and epithelial–mesenchymal transition. Conventional chemotherapeutic agents such as doxorubicin and paclitaxel are effective against BC cells; however, their clinical utility is limited by MDR, severe side effects including cardiotoxicity and neuropathy, and reduced efficacy in resistant tumors. To address these challenges, natural products interfere with resistance mechanisms through diverse pathways, inhibiting efflux pumps such as P-glycoprotein, restoring apoptosis, and modulating signal transduction pathways, including PI3K/Akt and NF- κ B. Furthermore, they induce autophagy, inhibit unregulated cell growth, and modify the tumor microenvironment to enhance therapeutic response. Compounds such as curcumin, silybin, apigenin, berberine, matrine, and β -elemene have been shown to improve the effectiveness of chemotherapy, whether used as monotherapies or in combination with conventional drugs, while exhibiting minimal side effects compared to synthetic medicines. In conclusion, secondary metabolites derived from plants possess significant potential to overcome MDR in breast cancer. Their ability to attack resistance-related mechanisms through multiple pathways not only enhances the effectiveness of current therapy but also offers a promising source of safer and more effective anticancer agents.